McGill University researchers have developed an innovative organ chip to revolutionize cancer treatment predictions. The new technology aims to address the individual variability in cancer treatment responses, especially for patients with advanced cancer who undergo neoadjuvant chemotherapy before surgery.
Traditional cancer treatments do not always yield the same results for everyone. Some tumors are resistant to standard chemotherapy, making it challenging for doctors to determine the most effective treatment approach for each patient. To tackle this issue, McGill University scientists have created an organ-on-a-chip device that can replicate a patient’s cancer and surrounding tissues outside the body, providing a more precise way to anticipate treatment outcomes.
Dr. Ferri, a leading expert in thoracic and upper gastrointestinal surgery at McGill University Health Centre, highlights the significance of this breakthrough, stating that for the first time, researchers can accurately predict how a patient’s cancer will respond to treatment by recreating the tumor environment with great precision.
The organ-on-a-chip technology combines organoids, miniature organ models derived from a patient’s tumor cells, with microfluidic organs-on-chips to mimic the complexity of the tumor microenvironment. By incorporating stromal cells and connective tissues surrounding the tumor, this advanced system offers a more comprehensive representation of the patient’s cancer, enhancing treatment prediction accuracy.
In a recent study involving eight patients, the researchers successfully replicated the patients’ responses to neoadjuvant chemotherapy within 12 days using the organ chip. The results demonstrated a direct correlation between the chip’s predictions and the patients’ actual treatment outcomes, showcasing the potential of this model to guide personalized cancer treatment decisions.
Dr. Ferri emphasizes the transformative impact of this technology on individualized cancer care, drug discovery, and precision oncology. The researchers envision using the organ chip to tailor treatments for patients, develop targeted therapies for specific cancer types, identify biomarkers for treatment monitoring, and enhance drug effectiveness in patients. Plans are underway to initiate a clinical trial within the next year to further explore the capabilities of this groundbreaking technology.
The study detailing the success of the organ chip in predicting treatment responses has been published in the Journal of Translational Medicine.
